Market Overview

Why Viking Therapeutics Is Trading Higher Today

Share:

Viking Therapeutics Inc (NASDAQ: VKTX) shares are trading higher on Tuesday, after Chardan initiated coverage on the company's stock with a Buy rating and $15 price target.

Viking Therapeutics is a health care service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta.

Viking Therapeutics shares trading up 4.5% at $6.63 on Tuesday. The stock has a 52-week range between $8.92 and $3.26.

Related Links:

Roche's Faster Coronavirus Test Receives FDA Emergency Use Authorization

Gilead's Remdesivir Granted FDA Emergency Use To Treat COVID-19

Latest Ratings for VKTX

DateFirmActionFromTo
Oct 2020Raymond JamesMaintainsStrong Buy
Aug 2020Chardan CapitalMaintainsBuy
Aug 2020HC Wainwright & Co.MaintainsBuy

View More Analyst Ratings for VKTX
View the Latest Analyst Ratings

 

Related Articles (VKTX)

View Comments and Join the Discussion!

Posted-In: why it's movingNews Price Target Initiation Analyst Ratings Movers Trading Ideas

Latest Ratings

StockFirmActionPT
HYMCBMO CapitalInitiates Coverage On
DEMorgan StanleyMaintains335.0
SBNYRaymond JamesMaintains138.0
CORTHC Wainwright & Co.Maintains32.0
CYBBFCitigroupDowngrades
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com